can compound pharmacies still make semaglutide Compounded With B6 (Pyridoxine) Novo Nordisk asks FDA to

Description

These claims often involve extensive review of medical records, autopsy findings, hospitalization history, prescription records, and expert medical opinions regarding causation

Gallbladder disease: Incretin-based therapies have been associated with an increased risk of cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation), as noted in the UK SmPCs for licensed comparators such as semaglutide and tirzepatide

95% CI, 0.44-0.81)

doi: 10.1016/j.jbc.2021.101388

While non-steroidal MRAs have not yet been investigated in type 1 diabetes, based on their observed benefits in type 2 diabetes and their mechanism of action, similar kidney-protective effects are anticipated, emphasising the need for dedicated studies with finerenone in people with type 1 diabetes and CKD, including their use in combination with other repurposed therapies such as SGLT2i and GLP1-RAs